Slide 1: OraSure 3Q21 Earnings
OraSure 3Q21 Earnings November 3, 2021 EXHIBIT 99.3
Slide 2: Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer This document contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual
Slide 3: 3Q21 Financial Results
3Q21 Financial Results FINANCIAL METRIC 3Q21 RESULTS 3Q20 RESULTS YEAR-OVER-YEAR GROWTH RATE 3Q21 Total Revenue $53.9 million $48.0 million 12% 3Q21 Total Revenue Excluding COVID-19 Product Revenue $40.0 million $29.1 million 37% 3Q21 COVID-19 Product Revenue $13.9 million $18.9 million -26%
Slide 4: Key Focus Areas to Drive Shareholder Value
Key Focus Areas to Drive Shareholder Value Expand Global Commercial Capabilities and Reach Drive Higher Growth Through Expanded R&D and M&A Expand Into New Sample Types and New Testing Modalities in Molecular Solutions Capitalize on COVID-19 Testing Opportunity To Fund Future Growth
Slide 5: Epidemiology Based Market Model Shows Longer COVID-19 Revenue Tail
Epidemiology Based Market Model Shows Longer COVID-19 Revenue Tail *Source: Epidemiology data, OSUR estimates
Slide 6: OraSure Signs Three Major Government Contracts in Quarter
OraSure Signs Three Major Government Contracts in Quarter $205 Million Department of Defense Procurement Contract $109 Million Department of Defense Contract To Expand InteliSwab™ Manufacturing Capacity $13.6 Million From BARDA To Get 510k Clearance and CLIA Waiver for InteliSwab™
Slide 7: Innovation in Molecular Solutions As Part of Multi-Omics Strategy
Innovation in Molecular Solutions As Part of Multi-Omics Strategy Meta-transcriptome Launch FDA Clearance for Gut Kit Colli-Pee™ studies in HPV New Cancer Chemistry
Slide 8: Expanding Global Reach To Broaden Market Access
Expanding Global Reach To Broaden Market Access We now have over 445 product registrations in 98 countries globally Pursuing CE Mark for InteliSwab™ Thailand Free Sales Certification and CE Mark for OraQuick® HIV Self Test Targeted 8 country launch for collection kits globally
Slide 9: Actively Evaluating Strategically Sound M&A Opportunities
Actively Evaluating Strategically Sound M&A Opportunities DIAGNOSTICS MOLECULAR SOLUTIONS Leverage existing end-to-end infrastructure from research to commercialization Support effortless testing in the POC and self-test settings New technology platforms enable menu expansion Support higher growth r
Slide 10: Revenue in Key Diagnostic Testing Categories
Revenue in Key Diagnostic Testing Categories Test Revenue (in mil.) Record DiagnosticTesting Revenue for the Company
Slide 11: Strong Core Growth in Molecular Solutions
Strong Core Growth in Molecular Solutions Test Revenue (in mil.) Overall Revenue - 4% Non-COVID Revenue +87% Continued Strong Core Growth in Molecular Kits and Services
Slide 12: Financial Results
Financial Results ‘Three Months Ended tember 30, Za 2020 Result of Operations Net evenues $ 3917 Cost of oducts and services sold DAB Goss profit 21a Opering expenses: Research and development 306 Seles ancl maxketing Bes Genemland adminis tative 149 Change in fer value ofacquistion seed contingent
Slide 13: Financial Guidance
Financial Guidance GUIDANCE METRIC FINANCIAL GUIDANCE 4Q21 Total Revenue $60 - $63 million FY21 InteliSwab™ Revenue ≈$30 million FY21 Total Revenue $230 - $233 million
Slide 14: Summary
Summary Commercially tied to high growth areas of healthcare such as consumer/clinical genomics and shift to direct-to-patient/near patient testing Increased investment in internal R&D pipeline and reinvigorating innovation Significant opportunity with InteliSwab™ to drive growth and fund additional
Slide 15: Q&A
Q&A OraSure Technologies oNAgenoTeK” Diversigen’ Wnovosanis